Diabetes drug 'significantly reverses memory loss' in mice with Alzheimer's

January 1, 2018, Lancaster University
One in three people will be diagnosed with Alzheimer's. Credit: Lancaster University

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action.

The research, published in Brain Research, could bring substantial improvements in the treatment of Alzheimer's disease through the use of a originally created to treat type 2 diabetes.

Lead researcher Professor Christian Holscher of Lancaster University in the UK said the novel treatment "holds clear promise of being developed into a new treatment for chronic neurodegenerative disorders such as Alzheimer's disease."

Alzheimer's disease is the most common cause of dementia and the numbers are expected to rise to two million people in the UK by 2051 according to Alzheimer's Society, who part- funded the research.

Dr Doug Brown, Director of Research and Development at Alzheimer's Society, said: ""With no new treatments in nearly 15 years, we need to find new ways of tackling Alzheimer's. It's imperative that we explore whether drugs developed to treat other conditions can benefit people with Alzheimer's and other forms of dementia. This approach to research could make it much quicker to get promising new drugs to the people who need them."

Although the benefits of these 'triple agonist' drugs have so far only been found in mice, other studies with existing such as liraglutide have shown real promise for people with Alzheimer's, so further development of this work is crucial."

This is the first time that a triple receptor drug has been used which acts in multiple ways to protect the brain from degeneration. It combines GLP-1, GIP and Glucagon which are all growth factors. Problems with growth factor signalling have been shown to be impaired in the brains of Alzheimer's patients.

Credit: Lancaster University

The study used APP/PS1 mice, which are transgenic mice that express human mutated genes that cause Alzheimer's. Those genes have been found in people who have a form of Alzheimer's that can be inherited. Aged in the advanced stages of neurodegeneration were treated.

In a maze test, learning and memory formation were much improved by the drug which also:-

  • enhanced levels of a brain growth factor which protects nerve cell functioning
  • reduced the amount of amyloid plaques in the brain linked with Alzheimer's
  • reduced both chronic inflammation and oxidative stress
  • slowed down the rate of nerve cell loss

Professor Holscher said: "These very promising outcomes demonstrate the efficacy of these novel multiple receptor drugs that originally were developed to treat type 2 diabetes but have shown consistent neuro- protective effects in several studies."

"Clinical studies with an older version of this drug type already showed very promising results in people with Alzheimer's disease or with mood disorders"

"Here we show that a novel triple receptor drug shows promise as a potential treatment for Alzheimer's but further dose-response tests and direct comparisons with other drugs have to be conducted in order to evaluate if this is superior to previous ones."

Type 2 diabetes is a risk factor for Alzheimer's and has been implicated in the progression of the disease. Impaired insulin has been linked to cerebral degenerative processes in type 2 diabetes and Alzheimer's disease. Insulin desensitisation has also been observed in the Alzheimer's disease brain. The desensitisation could play a role in the development of neurodegenerative disorders as insulin is a with neuroprotective properties.

Explore further: Diabetes drug could influence brain activity in Alzheimer's

More information: Jingjing Tai et al, Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease, Brain Research (2017). DOI: 10.1016/j.brainres.2017.10.012

Related Stories

Diabetes drug could influence brain activity in Alzheimer's

April 28, 2016
Researchers in Denmark have released findings from a small clinical trial of the diabetes drug liraglutide in people living with Alzheimer's disease.

Alzheimer's researchers investigate diabetes link in mice

June 22, 2016
Researchers in Aberdeen have highlighted a possible new link between Alzheimer's disease and diabetes according to a new study published today in the journal Diabetologia.

Experimental diabetes drug could help fight Alzheimer's disease

September 14, 2012
(Medical Xpress)—A drug designed for diabetes sufferers could have the potential to treat neurodegenerative diseases like Alzheimer's, a study by scientists at the University of Ulster has revealed.

Treatment approach used in cancer holds promise for Alzheimer's disease

October 21, 2016
Researchers have developed a novel treatment that could block the development of Alzheimer's disease using microscopic droplets of fat to carry drugs into the brain. This treatment approach, which is used to target drugs ...

Drug restores cells and memories in Alzheimer's mouse models

July 6, 2017
A new drug can restore memories and connections between brain cells in mice with a model of Alzheimer's disease, a new Yale-led study suggests.

Research points to new treatment strategy against Alzheimer's disease

September 7, 2016
New research suggests that Alzheimer's disease may trigger increased expression of an enzyme called lysozyme, which attempts to counteract amyloid build-up in the brain.

Recommended for you

Pregnancy history may be tied to Alzheimer's disease

July 18, 2018
A woman's history of pregnancy may affect her risk of Alzheimer's disease decades later, according to a study published in the July 18, 2018, online issue of Neurology, the medical journal of the American Academy of Neurology. ...

Molecular tracer, seen with PET scan, shows concentrations of abnormal proteins

July 17, 2018
In a small study of military personnel who had suffered head trauma and had reported memory and mood problems, UCLA researchers found brain changes similar to those seen in retired football players with suspected chronic ...

Yale-developed test for Alzheimer's disease directly measures synaptic loss

July 16, 2018
Yale researchers have tested a new method for directly measuring synaptic loss in individuals with Alzheimer's disease. The method, which uses PET imaging technology to scan for a specific protein in the brain linked to synapses, ...

New study highlights Alzheimer's herpes link, experts say

July 12, 2018
A new commentary by scientists at the Universities of Manchester and Edinburgh on a study by Taiwanese epidemiologists supports the viability of a potential way to reduce the risk of Alzheimer's disease.

Practice imperfect—repeated cognitive testing can obscure early signs of dementia

July 12, 2018
Alzheimer's disease (AD) is a progressive, neurodegenerative condition that often begins with mild cognitive impairment or MCI, making early and repeated assessments of cognitive change crucial to diagnosis and treatment.

The 'Big Bang' of Alzheimer's: Scientists ID genesis of disease, focus efforts on shape-shifting tau

July 10, 2018
Scientists have discovered a "Big Bang" of Alzheimer's disease – the precise point at which a healthy protein becomes toxic but has not yet formed deadly tangles in the brain.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

tekram
5 / 5 (1) Jan 01, 2018
Here we test the effects of a triple receptor agonist (TA), which activates GIP-1, GIP and glucagon receptors at the same time. This novel drug has been developed as a potential treatment for diabetes (Finan et al., 2015).

The TA is a glucagon based agonist:
http://glucagon.c...nist.pdf
"Treatment with the triagonist lowered body weight by 15.1%, a substantial potentiation compared with liraglutide and both GIP/glucagon and GLP-1/glucagon coagonists. The triagonist was the only compound to markedly improve glucose tolerance (Supplementary Fig. 3b) and reduce food intake (Supplementary Fig. 3d) at this low dose."

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.